2024 ICD-10-CM Diagnosis Code T38.7X5S

Adverse effect of androgens and anabolic congeners, sequela

ICD-10-CM Code:
T38.7X5S
ICD-10 Code for:
Adverse effect of androgens and anabolic congeners, sequela
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
        (T38)

T38.7X5S is a billable diagnosis code used to specify a medical diagnosis of adverse effect of androgens and anabolic congeners, sequela. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T38.7X5S is a sequela code, includes a 7th character and should be used for complications that arise as a direct result of a condition like adverse effect of androgens and anabolic congeners. According to ICD-10-CM Guidelines a "sequela" code should be used for chronic or residual conditions that are complications of an initial acute disease, illness or injury. The most common sequela is pain. Usually, two diagnosis codes are needed when reporting sequela. The first code describes the nature of the sequela while the second code describes the sequela or late effect.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • 46,XX disorder of sex development caused by testosterone and/or testosterone derivative
  • Anabolic steroids adverse reaction
  • Androgen adverse reaction
  • Androgen-induced testicular atrophy
  • Anti-androgens adverse reaction
  • Atrophy of testis
  • Bicalutamide adverse reaction
  • Drostanolone propionate adverse reaction
  • Intramuscular testosterone adverse reaction
  • Mesterolone adverse reaction
  • Methyltestosterone adverse reaction
  • Nandrolone adverse reaction
  • Oral testosterone adverse reaction
  • Oxymetholone adverse reaction
  • Stanozolol adverse reaction
  • Testosterone adverse reaction
  • Testosterone implant adverse reaction
  • Testosterone patch adverse reaction
  • Tibolone adverse reaction

Clinical Classification

Clinical Information

  • Androsterone

    a metabolite of testosterone or androstenedione with a 3-alpha-hydroxyl group and without the double bond. the 3-beta hydroxyl isomer is epiandrosterone.
  • Glucuronosyltransferase

    a family of enzymes accepting a wide range of substrates, including phenols, alcohols, amines, and fatty acids. they function as drug-metabolizing enzymes that catalyze the conjugation of udpglucuronic acid to a variety of endogenous and exogenous compounds. ec 2.4.1.17.
  • Ethylestrenol

    an anabolic steroid with some progestational activity and little androgenic effect.
  • Norethandrolone

    a synthetic hormone with anabolic and androgenic properties and moderate progestational activity.
  • Fluoxymesterone

    an anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
  • Mesterolone

    17 beta-hydroxy-1 alpha-methyl-5 alpha-androstan-3-one. a synthetic steroid with anabolic and androgenic activities.
  • Methandriol

    a synthetic steroid with anabolic and androgenic properties. (from martindale, the extra pharmacopoeia, 30th ed, p1188)
  • Methandrostenolone

    a synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. it has little progestational activity. (from martindale, the extra pharmacopoeia, 30th ed, p1188)
  • Methenolone

    a synthetic steroid that has been used for its anabolic action.
  • Methyltestosterone

    a synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (antineoplastic agents, hormonal).
  • Nandrolone

    c18 steroid with androgenic and anabolic properties. it is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position.
  • Nandrolone Decanoate

    decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat wasting syndrome associated with severe chronic illness or hiv infection (hiv wasting syndrome). it may also be used in the treatment of postmenopausal osteoporosis.
  • Oxandrolone

    a synthetic hormone with anabolic and androgenic properties.
  • Oxymetholone

    a synthetic hormone with anabolic and androgenic properties. it is used mainly in the treatment of anemias. according to the fourth annual report on carcinogens (ntp 85-002), this compound may reasonably be anticipated to be a carcinogen. (from merck index, 11th ed)
  • Stanozolol

    a synthetic steroid that has anabolic and androgenic properties. (from martindale, the extra pharmacopoeia, 30th ed, p1194)
  • Testolactone

    an antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
  • 17-Hydroxysteroid Dehydrogenases

    a class of enzymes that catalyzes the oxidation of 17-hydroxysteroids to 17-ketosteroids. ec 1.1.-.
  • 3-Oxo-5-alpha-Steroid 4-Dehydrogenase

    an enzyme that catalyzes the reduction of testosterone to 5-alpha dihydrotestosterone.
  • 5-alpha Reductase Inhibitors

    drugs that inhibit 3-oxo-5-alpha-steroid 4-dehydrogenase. they are commonly used to reduce the production of dihydrotestosterone.
  • Clusterin

    a highly conserved heterodimeric glycoprotein that is differentially expressed during many severe physiological disturbance states such as cancer; apoptosis; and various neurological disorders. clusterin is ubiquitously expressed and appears to function as a secreted molecular chaperone.
  • Receptors, Androgen

    proteins, generally found in the cytoplasm, that specifically bind androgens and mediate their cellular actions. the complex of the androgen and receptor migrates to the cell nucleus where it induces transcription of specific segments of dna.
  • Sex Hormone-Binding Globulin

    a glycoprotein migrating as a beta-globulin. its molecular weight, 52,000 or 95,000-115,000, indicates that it exists as a dimer. the protein binds testosterone, dihydrotestosterone, and estradiol in the plasma. sex hormone-binding protein has the same amino acid sequence as androgen-binding protein. they differ by their sites of synthesis and post-translational oligosaccharide modifications.
  • Steroid 16-alpha-Hydroxylase

    a liver microsomal cytochrome p450 enzyme that catalyzes the 16-alpha-hydroxylation of a broad spectrum of steroids, fatty acids, and xenobiotics in the presence of molecular oxygen and nadph-ferrihemoprotein reductase. this enzyme is encoded by a number of genes from several cyp2 subfamilies.
  • Testosterone

    a potent androgenic steroid and major product secreted by the leydig cells of the testis. its production is stimulated by luteinizing hormone from the pituitary gland. in turn, testosterone exerts feedback control of the pituitary lh and fsh secretion. depending on the tissues, testosterone can be further converted to dihydrotestosterone or estradiol.
  • Testosterone Congeners

    steroidal compounds related to testosterone, the major mammalian male sex hormone. testosterone congeners include important testosterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with androgenic activities.
  • Testosterone Propionate

    an ester of testosterone with a propionate substitution at the 17-beta position.
  • Zeranol

    a non-steroidal estrogen analog.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T38.7X5S is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T38.7X5S to ICD-9-CM

  • ICD-9-CM Code: 909.5 - Lte efct advrs efct drug
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.
  • ICD-9-CM Code: E932.1 - Adv eff androgens
    Combination Flag - Multiple codes are needed to describe the source diagnosis code. Correct coding should be done based on contextual judgment.

Table of Drugs and Chemicals

The parent code T38.7X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
Anabolic steroidT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
AndrogenT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Androgen-estrogen mixtureT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
AndrostaloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
AndrostanoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
AndrosteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
CalusteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Chlorodehydro-methyltestosteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Congener, anabolicT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
DromostanoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
DrostanoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
DurabolinT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
EpitiostanolT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
EstanozololT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
EthylestrenolT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
FluoxymesteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MacrolideT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Macrolide
  »anabolic drug
T38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Macrolide
  »antibiotic
T38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MepitiostaneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MestanoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MesteroloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MetandienoneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MetandrostenoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MetenoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MethandienoneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MethandriolT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MethandrostenoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MethenoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
MethyltestosteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
NandroloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
NorethandroloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
Nortestosterone (furanpropionate)T38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
OxandroloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
OxymesteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
OxymetholoneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
PrasteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
StanoloneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
StanozololT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
TestolactoneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
TestosteroneT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6
ZeranolT38.7X1T38.7X2T38.7X3T38.7X4T38.7X5T38.7X6

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.